To include your compound in the COVID-19 Resource Center, submit it here.

Biolife Science, Imugene deal

Drug delivery company Imugene will acquire Biolife for 300 million shares of

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE